HOME Top Market Reports Nuclear Medicine/Radiopharmaceuticals Market by Type (Diagnostic (SPECT - Technetium, PET - F-18), Therapeutic (Beta Emitters - I-131, Alpha Emitters, Brachytherapy - Y-90) & by Application (Oncology, Thyroid, Cardiology) - Global Forecasts to 2020

Nuclear Medicine/Radiopharmaceuticals Market by Type (Diagnostic (SPECT - Technetium, PET - F-18), Therapeutic (Beta Emitters - I-131, Alpha Emitters, Brachytherapy - Y-90) & by Application (Oncology, Thyroid, Cardiology) - Global Forecasts to 2020

By: marketsandmarkets.com
Publishing Date: July 2015
Report Code: PH 3590

 

  Speak to Analyst Enquiry Before Buying  
purchase report
download pdf  request for customisation


The nuclear medicine/radiopharmaceuticals market is segmented on the basis of type, application, and region. The global radiopharmaceuticals market is valued at $4.50 Billion in 2015 and is poised to grow at a CAGR of 9.1% during the forecasted period.

Factors such as advances in radiotracers, alpha radio immunotherapy-based targeted cancer treatment, and increasing number of patients with cancer and cardiovascular aliments are driving the growth of this market. Moreover, potential radioisotopes in the pipeline, high demand from emerging countries, and advances in neurological applications are likely to create huge opportunities for this market in the coming years. However, factors such as shorter half-life of radiopharmaceuticals, stringent regulatory guidelines, and competition from conventional diagnostic procedures are hindering the growth of nuclear medicine market.

Some of the major players in the global nuclear medicine market include Cardinal Health, Inc. (U.S.), GE Healthcare (U.K.), Bracco Imaging S.p.A (Italy), Eczacibasi-Monrol Nuclear Products (Turkey), Nordion, Inc. (Canada), Advanced Accelerator Applications S.A. (France), Bayer Healthcare (Germany), Lantheus Medical Imaging, Inc. (U.S.), IBA Molecular Imaging (Belgium), and Mallinckrodt plc (Ireland).

Scope of the Report:

This research report categorizes the radiopharmaceuticals market into the following segments and subsegments:

Nuclear Medicine/Radiopharmaceuticals Market, by Type

  • Diagnostics
      • SPECT Radiopharmaceuticals
      • Tc-99
      • Tl-201
      • Ga-67
      • I-123
      • Others
      • PET Radiopharmaceuticals
      • F-18
      • Ru-82
      • Others
  • Therapeutics
      • Beta Emitters
      • I-131
      • Sm-153
      • Rh-186
      • Y-90
      • Lu-177
      • Others
      • Alpha Emitters
      • Ra-223
      • Brachytherapy Isotopes
      • I-125
      • Ir-192
      • Pa-103
      • Cs-131
      • Others

Nuclear Medicine/Radiopharmaceuticals Market, by Procedural Volume

  • Diagnostics
      • SPECT Radiopharmaceuticals
      • PET Radiopharmaceuticals
  • Therapeutics
      • Beta Emitters
      • Alpha Emitters
      • Brachytherapy Isotopes

Nuclear Medicine/Radiopharmaceuticals Market, by Application

  • Diagnostics
      • SPECT
      • Cardiology
      • Lymphoma
      • Thyroid
      • Neurology
      • Others
      • PET
      • Oncology
      • Cardiology
      • Neurology
      • Others
  • Therapeutics
      • Thyroid
      • Bone Metastasis
      • Lymphoma
      • Endocrine Tumors
      • Others

Nuclear Medicine/Radiopharmaceuticals Market, by Region

  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World (RoW)

Table of Contents

1 Introduction (Page No. - 19)
    1.1 Objectives of Study
    1.2 Market Definition
    1.3 Market Scope
           1.3.1 Markets Covered
           1.3.2 Years Considered for the Study
    1.4 Currency
    1.5 Limitations
    1.6 Stakeholders

2 Research Methodology (Page No. - 23)
    2.1 Research Methodology Steps
    2.2 Secondary and Primary Research Methodology
           2.2.1 Secondary Research
           2.2.2 Primary Research
           2.2.3 Key Industry Insights
    2.3 Key Data From Primary Sources
    2.4 Key Insights From Primary Sources
    2.5 Market Size Estimation Methodology
           2.5.1 Research Design
    2.6 Market Data Validation and Triangulation
    2.7 Assumptions for the Study

3 Executive Summary (Page No. - 33)
    3.1 Introduction
    3.2 Current Scenario
    3.3 Future Outlook
    3.4 Conclusion

4 Premium Insights (Page No. - 39)
    4.1 Global Nuclear Medicine Market
    4.2 SPECT Nuclear Medicine/Radiopharmaceuticals Diagnostics Market, By Region and Application
    4.3 Regional Snapshot of the Nuclear Medicine/Radiopharmaceuticals Market
    4.4 Nuclear Medicine/Radiopharmaceuticals Market, By Type (2015 vs. 2020)

5 Market Overview (Page No. - 43)
    5.1 Introduction
    5.2 Market Segmentation
    5.3 Market Dynamics
           5.3.1 Drivers
                    5.3.1.1 Increasing Preference for SPECT and PET Scans
                    5.3.1.2 Advances in Radiotracers
                    5.3.1.3 Alpha Radio Immunotherapy-Based Targeted Cancer Treatment
                    5.3.1.4 Increasing Incidence of Cancer and Cardiac Ailments
           5.3.2 Restraints
                    5.3.2.1 Shorter Half-Life of Radiopharmaceuticals Restricts Its Usage
                    5.3.2.2 Stringent Regulatory and Gmp Guidelines
                    5.3.2.3 Competition From Conventional Diagnostic Procedures
           5.3.3 Opportunities
                    5.3.3.1 Potential Radioisotopes in the Pipeline
                    5.3.3.2 High Demand in Emerging Markets
                    5.3.3.3 Neurological Applications
           5.3.4 Threat
                    5.3.4.1 Shutdown of Nuclear Reactors

6 Global Nuclear Medicine/Radiopharmaceuticals Market, By Type (Page No. - 56)
    6.1 Introduction
    6.2 Nuclear Medicine/Radiopharmaceuticals Diagnostic Market
           6.2.1 SPECT
                    6.2.1.1 Technetium-99m (TC-99m)
                    6.2.1.2 Thallium-201 (TL-201)
                    6.2.1.3 GAllium-67 (GA-67)
                    6.2.1.4 Iodine (I-123)
                    6.2.1.5 Others
           6.2.2 PET Radiopharmaceuticals
                    6.2.2.1 Fluorine-18 (F-18)
                    6.2.2.2 Rubidium-82 (RB-82)
                    6.2.2.3 Others
    6.3 Nuclear Medicine Therapeutic Isotopes Market
           6.3.1 Beta Emitters
                    6.3.1.1 Iodine-131 (I-131)
                    6.3.1.2 Yttrium-90 (Y-90)
                    6.3.1.3 Samarium-153 (SM-153)
                    6.3.1.4 Rhenium-186 (Re-186)
                    6.3.1.5 Lutetium-177 (Lu-177)
                    6.3.1.6 Others
           6.3.2 Alpha Emitters
                    6.3.2.1 Radium-223 (RA-223)
           6.3.3 Brachytherapy
                    6.3.3.1 Cesium-131
                    6.3.3.2 Iodine-125
                    6.3.3.3 Palladium-103
                    6.3.3.4 Iridium-192
                    6.3.3.5 Others

7 Global Nuclear Medicine/Radiopharmaceuticals Market, By Procedural Volume (Page No. - 88)
    7.1 Introduction
    7.2 Diagnostics Market
           7.2.1 SPECT Radiopharmaceuticals
           7.2.2 PET Radiopharmaceuticals
    7.3 Therapeutic Market
           7.3.1 Beta Emitters
           7.3.2 Alpha Emitters
           7.3.3 Brachytherapy

8 Global Nuclear Medicine/Radiopharmaceuticals Market, By Application (Page No. - 101)
    8.1 Introduction
    8.2 Diagnostics
           8.2.1 SPECT
                    8.2.1.1 Cardiology
                    8.2.1.2 Lymphoma
                    8.2.1.3 Neurology
                    8.2.1.4 Thyroid
                    8.2.1.5 Other Diagnostic Applications
           8.2.2 PET
                    8.2.2.1 Oncology
                    8.2.2.2 Cardiology
                    8.2.2.3 Neurology
                    8.2.2.4 Other PET Applications
    8.3 Therapeutics
           8.3.1 Thyroid
           8.3.2 Bone Metastasis
           8.3.3 Lymphoma
           8.3.4 Endocrine Tumors
           8.3.5 Other Therapeutic Applications

9 Global Nuclear Medicine/Radiopharmaceuticals Market, By Region (Page No. - 129)
    9.1 Introduction
    9.2 Diagnostic Market
           9.2.1 North America
                    9.2.1.1 Development of Mo-99 Production Facilities in the U.S.
                    9.2.1.2 Fda Approvals of New Radiopharmaceuticals
                    9.2.1.3 Extension of Operations in the Canadian National Research Universal (NRU) Reactor
                    9.2.1.4 Development of Alternative Medical Isotope Technologies in Canada
           9.2.2 Europe
                    9.2.2.1 Increasing Acceptability of 18f-Fdg PET-CT in the U.K.
                    9.2.2.2 Shutdown of French Nuclear Reactor
                    9.2.2.3 New Irradiation Facility in Germany
           9.2.3 Asia-Pacific
                    9.2.3.1 Introduction of New Cost-Effective TC-99 Generators in India
                    9.2.3.2 High Incidence of Cancer and Cardiovascular Disease in China
                    9.2.3.3 Increasing Mo-99 Production in Australia
                    9.2.3.4 Initiatives to Promote Health in Asia-Pacific
           9.2.4 Rest of the World
                    9.2.4.1 Development of Multipurpose Research Reactor in Brazil
                    9.2.4.2 Argentina’s Increasing Irradiation Capacity
                    9.2.4.3 Conversion of the Safari 1 Reactor, From Heu-Based Mo-99 Production to Leu
    9.3 Therapeutic Market
           9.3.1 North America
                    9.3.1.1 Fda Approval for Alpha Emitters in the U.S.
                    9.3.1.2 Therapeutic Nuclear Medicine, an Alternative Choice of Treatment in Oncology
                    9.3.1.3 Increase in the Incidence of Thyroid Cancer
                    9.3.1.4 Expertise in Isotope Production
           9.7.5 Government Initiatives
           9.7.6 High Incidence of Cancer
           9.3.2 Europe
                    9.3.2.1 Increasing Awareness of Radioisotope Therapy in the U.K.
                    9.3.2.2 Adverse Reactions to Radiopharmaceuticals in France
                    9.3.2.3 Radionuklidtherapeutika—Research Program Conducted in Germany
                    9.3.2.4 Russia, an Upcoming Country for Radionuclide Therapy
           9.3.3 Asia-Pacific
                    9.3.3.1 Increased Production of Radiopharmaceuticals for Therapeutic Purposes in India
                    9.3.3.2 Aging Population and Increasing Cancer Incidence
                    9.3.3.3 Approval of Radium (223 RA) Dichloride By the Therapeutic Goods Administration (TGA)
           9.3.4 Rest of the World(RoW)
                    9.3.4.1 Growing Aging Population
                    9.3.4.2 Increase in Cancer Incidences

10 Competitive Landscape (Page No. - 177)
     10.1 Overview
     10.2 Market Share Analysis
             10.2.1 Introduction
             10.2.2 Cardinal Health, Inc.
             10.2.3 Mallinckrodt PLC
             10.2.4 GE Healthcare
             10.2.5 Lantheus Medical Imaging, Inc.
             10.2.6 Bayer Healthcare
     10.3 Competitive Situation and Trends
             10.3.1 Introduction
             10.3.2 Agreements, Contracts, and Partnerships
             10.3.3 Acquisitions
             10.3.4 Market Development
             10.3.5 Expansion
             10.3.6 New Product Launches
             10.3.7 Others

11 Company Profiles (Page No. - 193)
     11.1 Introduction
     11.2 Cardinal Health, Inc.
             11.2.1 Business Overview
             11.2.2 Products and Services
             11.2.3 Recent Developments
             11.2.4 MnM View
     11.3 Mallinckrodt PLC
             11.3.1 Business Overview
             11.3.2 Product Offerings
             11.3.3 Recent Developments
             11.3.4 MnM View
     11.4 GE Healthcare
             11.4.1 Business Overview
             11.4.2 Product Portfolio
             11.4.3 Recent Developments
             11.4.4 MnM View
     11.5 Lantheus Medical Imaging, Inc.
             11.5.1 Business Overview
             11.5.2 Product Offerings
             11.5.3 Recent Developments
             11.5.4 MnM View
     11.6 Bayer Healthcare
             11.6.1 Business Overview
             11.6.2 Product Offerings
             11.6.3 Recent Developments
             11.6.4 MnM View
     11.7 Bracco Imaging S.P.A
             11.7.1 Business Overview
             11.7.2 Product Offerings
             11.7.3 Recent Developments
     11.8 Eczcibasi-Monrol Nuclear Products
             11.8.1 Business Overview
             11.8.2 Products and Services
             11.8.3 Recent Developments
     11.9 Nordion, Inc.
             11.9.1 Business Overview
             11.9.2 Product Offerings
             11.9.3 Recent Developments
     11.10 Advanced Accelerator Applications S.A.
             11.10.1 Business Overview
             11.10.2 Product Offerings
             11.10.3 Recent Developments
     11.11 IBA Molecular Imaging
             11.11.1 Business Overview
             11.11.2 Product Offerings
             11.11.3 Recent Developments

12 Appendix (Page No. - 218)
     12.1 Discussion Guide
     12.2 Company Developments (2012–2015)
             12.2.1 Cardinal Health, Inc.
             12.2.2 Bayer Healthcare
     12.3 Available Customizations
     12.4 Introducing RT: Real-Time Market Intelligence
     12.5 Related Reports


List of Tables (113 Tables)

Table 1 Alpha Radio Immunotherapy-Based Targeted Cancer Treatment to Boost the Growth of the Radiopharmaceuticals Market
Table 2 Shorter Half-Life of Radiopharmaceuticals Restraining the Growth of the Nuclear Medicine Market
Table 3 Potential Radioisotopes in the Pipeline Offer Significant Growth Opportunities for the Nuclear Medicine Market
Table 4 Shutdown of Nuclear Reactors is A Major Challenge in This Market
Table 5 Global Nuclear Medicine Market Size, By Region, 2013-2020 ($Million)
Table 6 Global Radiopharmaceuticals Market Size, By Type, 2013-2020 ($Million)
Table 7 Global Radiopharmaceuticals Market Size for Diagnostic Segment, By Region, 2013-2020 ($Million)
Table 8 Global Radiopharmaceuticals Market Size for Diagnostic Isotopes, By Type, 2013-2020 ($Million)
Table 9 Global Radiopharmaceuticals Market Size for SPECT, By Region, 2013-2020 ($Million)
Table 10 Global Nuclear Medicine Market Size for SPECT, By Isotope Type, 2013-2020 ($Million)
Table 11 Global SPECT Market Size for Technetium-99m Isotopes, By Region, 2013-2020 ($Million)
Table 12 Global SPECT Market Size for Thallium-201 Isotopes, By Region, 2013-2020 ($Million)
Table 13 Global SPECT Market Size for Gallium-67 Isotopes, By Region, 2013-2020 ($Million)
Table 14 Global SPECT Market Size for Iodine-123 Isotopes, By Region, 2013-2020 ($Million)
Table 15 Global SPECT Market Size for Other Isotopes, By Region, 2013-2020 ($Million)
Table 16 Global Nuclear Medicine Market Size for PET, By Region, 2013-2020 ($Million)
Table 17 Global Nuclear Medicine Market Size for PET, By Isotope, 2013-2020 ($Million)
Table 18 Global PET Market Size for Fluorine-18 Isotopes, By Region, 2013-2020 ($Million)
Table 19 Global PET Market Size for Rubidium-82 Isotopes, By Region, 2013-2020 ($Million)
Table 20 Global PET Market Size for Other Isotopes, By Region, 2013-2020 ($Million)
Table 21 Global Radiopharmaceuticals Market Size for Therapeutic Isotopes, By Region, 2013-2020 ($Million)
Table 22 Global Radiopharmaceuticals Market Size for Therapeutic Isotopes, By Type, 2013-2020 ($Million)
Table 23 Global Beta Emitters Market Size, By Region, 2013-2020 ($Million)
Table 24 Global Beta Emitters Market Size, By Isotope, 2013-2020 ($Million)
Table 25 Global Beta Emitters Market Size for Iodine-131 Isotopes, By Region, 2013-2020 ($Million)
Table 26 Global Beta Emitters Market Size for Yttrium-90 Isotopes, By Region, 2013-2020 ($Million)
Table 27 Global Beta Emitters Market Size for Samarium-153 Isotopes, By Region, 2013-2020 ($Million)
Table 28 Global Beta Emitters Market Size for Rhenium-186 Isotopes, By Region, 2013-2020 ($Million)
Table 29 Global Beta Emitters Market Size for Lutetium-177 Isotopes, By Region, 2013-2020 ($Million)
Table 30 Global Beta Emitters Market Size for Other Isotopes, By Region, 2013-2020 ($Million)
Table 31 Global Alpha Emitters Market Size, By Region, 2013-2020 ($Million)
Table 32 Global Radiopharmaceuticals Market Size for Brachytherapy, By Region, 2013-2020 ($Million)
Table 33 Global Radiopharmaceuticals Market Size for Brachytherapy, By Isotopes, 2013-2020 ($Million)
Table 34 Global Brachytherapy Market Size for Cesium-131 Isotopes, By Region, 2013-2020 ($Million)
Table 35 Global Brachytherapy Market Size for Iodine-125 Isotopes, By Region, 2013-2020 ($Million)
Table 36 Global Brachytherapy Market Size for Palladium-103 Isotopes, By Region, 2013-2020 ($Million)
Table 37 Global Brachytherapy Market Size for Iridium-192 Isotopes, By Region, 2013-2020 ($Million)
Table 38 Global Brachytherapy Market Size for Other Isotopes, By Region, 2013-2020 ($Million)
Table 39 Radiopharmaceuticals Procedures Market Size, By Region, 2013–2020 (Thousand)
Table 40 Radiopharmaceuticals Diagnostic Procedures Market Size, By Type, 2013–2020 (Thousand)
Table 41 Radiopharmaceuticals Diagnostic Procedures Market Size, By Region, 2013–2020 (Thousand)
Table 42 Radiopharmaceuticals SPECT Procedures Market Size, By Type, 2013–2020 (Thousand)
Table 43 Nuclear Medicine SPECT Procedures Market Size, By Region, 2013–2020 (Thousand)
Table 44 Nuclear Medicine PET Procedures Market Size, By Type, 2013–2020 (Thousand)
Table 45 Radiopharmaceuticals PET Procedures Market Size, By Region, 2013–2020 (Thousand)
Table 46 Nuclear Medicine Therapeutic Procedures Market Size, By Type, 2013–2020 (Thousand)
Table 47 Radiopharmaceuticals Therapeutic Procedures Market Size, By Region, 2013–2020 (Thousand)
Table 48 Radiopharmaceuticals Beta Emitters Procedure Market Size, By Type, 2013–2020 (Thousand)
Table 49 Nuclear Medicine Beta Emitters Procedure Market Size, By Region, 2013–2020 (Thousand)
Table 50 Radiopharmaceuticals Alpha Emitters Procedure Market Size, By Type, 2013–2020 (Thousand)
Table 51 Nuclear Medicine Alpha Emitters Procedure Market Size, By Region, 2013–2020 (Thousand)
Table 52 Radiopharmaceuticals Brachytherapy Procedures Market Size, By Type, 2013–2020 (Thousand)
Table 53 Radiopharmaceuticals Brachytherapy Procedures Market Size, By Region, 2013–2020 (Thousand)
Table 54 Segmentation of Nuclear Medicine/Radiopharmaceuticals Market for SPECT Applications, By Type
Table 55 Nuclear Medicine/Radiophamaceuticals Market Size for SPECT Applications, By Region, 2013–2020 ($Million)
Table 56 Nuclear Medicine Market Size for SPECT Applications, By Type, 2013-2020 ($Million)
Table 57 Nuclear Medicine Market Size for Cardiology SPECT Applications, By Region, 2013–2020 ($Million)
Table 58 Nuclear Medicine/Radiopharmaceuticals Market Size for Lymphoma SPECT Applications, By Region, 2013–2020 ($Million)
Table 59 Market Size for Neurology SPECT Applications, By Region, 2013–2020 ($Million)
Table 60 Market Size for Thyroid SPECT Applications, By Region, 2013–2020 ($Million)
Table 61 Market Size for Other SPECT Applications, By Region, 2013–2020 ($Million)
Table 62 Nuclear Medicine/Radiopharmaceuticals Market Segmentation of PET, By Application
Table 63 Nuclear Medicine/Radiopharmaceuticals Market Size for PET Applications, By Region, 2013–2020 ($Million)
Table 64 Nuclear Medicine/Radiopharmaceuticals Market Size for PET Applications, By Type, 2013-2020 ($Million)
Table 65 Market Size for Oncology PET Applications, By Region, 2013–2020 ($Million)
Table 66 Market Size for Cardiology PET Applications, By Region, 2013–2020 ($Million)
Table 67 Market Size for Neurology PET Applications, By Region, 2013–2020 ($Million)
Table 68 Market Size for Other PET Applications, By Region, 2013–2020 ($Million)
Table 69 Radiopharmaceuticals Therapeutic Applications Market Segmentation, By Type
Table 70 Nuclear Medicine Market Size for Therapeutic Applications, By Region, 2013–2020 ($Million)
Table 71 Nuclear Medicine Market Size for Therapeutic Applications, By Type, 2013–2020($Million)
Table 72 Market Size for Thyroid Therapeutic Applications, By Region, 2013–2020 ($Million)
Table 73 Radiopharmaceuticals Market Size for Bone Metastasis Therapeutic Applications, By Region, 2013–2020 ($Million)
Table 74 Market Size for Lymphoma Therapeutic Applications, By Region, 2013–2020 ($Million)
Table 75 Radiopharmaceuticals Market Size for Endocrine Tumor Therapeutic Applications, By Region, 2013–2020 ($Million)
Table 76 Market Size for Other Therapeutic Applications, By Region, 2013–2020 ($Million)
Table 77 Global Nuclear Medicine Market Size, By Type, 2013-2020 ($Million)
Table 78 North America: Nuclear Medicine Diagnostic Market Size, By Type, 2013-2020 ($Million)
Table 79 North America: Nuclear Medicine SPECT Radiopharmaceuticals Market Size, By Type, 2013-2020 ($Million)
Table 80 North America: Nuclear Medicine PET Radiopharmaceuticals Market Size, By Type, 2013-2020 ($Million)
Table 81 North America: Nuclear Medicine SPECT Radiopharmaceuticals Market Size, By Application, 2013-2020 ($Million)
Table 82 North America: Nuclear Medicine PET Radiopharmaceuticals Market Size, By Application, 2013-2020 ($Million)
Table 83 Europe: Nuclear Medicine Diagnostic Market Size, By Type, 2013-2020 ($Million)
Table 84 Europe: Nuclear Medicine SPECT Radiopharmaceuticals Market Size, By Type, 2013-2020 ($Million)
Table 85 Europe: Nuclear Medicine PET Radiopharmaceuticals Market Size, By Type, 2013-2020 ($Million)
Table 86 Europe: Nuclear Medicine SPECT Radiopharmaceuticals Market Size, By Application, 2013-2020 ($Million)
Table 87 Europe: Nuclear Medicine PET Radiopharmaceuticals Market Size, By Application, 2013-2020 ($Million)
Table 88 Asia-Pacific: Radiopharmaceuticals Diagnostic Market Size, By Type, 2013-2020 ($Million)
Table 89 Asia-Pacific: Nuclear Medicine SPECT Radiopharmaceuticals Market Size, By Type, 2013-2020 ($Million)
Table 90 Asia-Pacific: Nuclear Medicine PET Radiopharmaceuticals Market Size, By Type, 2013-2020 ($Million)
Table 91 Asia-Pacific: Nuclear Medicine SPECT Radiopharmaceuticals Market Size, By Application, 2013-2020 ($Million)
Table 92 Asia-Pacific: Nuclear Medicine PET Radiopharmaceuticals Market Size, By Application, 2013-2020 ($Million)
Table 93 RoW: Nuclear Medicine Diagnostic Market Size, By Type, 2013-2020 ($Million)
Table 94 RoW: Nuclear Medicine SPECT Radiopharmaceuticals Market Size, By Type, 2013-2020 ($Million)
Table 95 RoW: Nuclear Medicine PET Radiopharmaceuticals Market Size, By Type, 2013-2020 ($Million)
Table 96 RoW: Nuclear Medicine SPECT Radiopharmaceuticals Market Size, By Application, 2013-2020 ($Million)
Table 97 RoW: Nuclear Medicine PET Radiopharmaceuticals Market Size, By Application, 2013-2020 ($Million)
Table 98 North America: Nuclear Medicine Therapeutic Market Size, By Type, 2013–2020 ($Million)
Table 99 North America: Nuclear Medicine Beta Emitters Market Size, By Type, 2013–2020 ($Million)
Table 100 North America: Nuclear Medicine Brachytherapy Market Size, By Type, 2013–2020 ($Million)
Table 101 North America: Nuclear Medicine Therapeutic Market Size, By Type, 2013–2020 ($Million)
Table 102 Europe: Radiopharmaceuticals Therapeutic Market Size, By Type, 2013–2020 ($Million)
Table 103 Europe: Nuclear Medicine Beta Emitters Market Size, By Type, 2013–2020 ($Million)
Table 104 Europe: Nuclear Medicine Brachytherapy Market Size, By Type, 2013–2020 ($Million)
Table 105 Europe: Radiopharmaceuticals Therapeutic Market Size, By Application, 2013–2020 ($Million)
Table 106 Asia-Pacific: Nuclear Medicine/Radiopharmaceutical Therapeutic Market Size, By Type, 2013–2020 ($Million)
Table 107 Asia-Pacific: Radiopharmaceutical Beta Emitters Market Size, By Type, 2013–2020 ($Million)
Table 108 Asia-Pacific: Radiopharmaceutical Brachytherapy Market Size, By Type, 2013–2020 ($Million)
Table 109 Asia-Pacific: Nuclear Medicine/Radiopharmaceutical Therapeutic Market Size, By Application, 2013–2020 ($Million)
Table 110 RoW: Radiopharmaceutical Therapeutic Market Size, By Type, 2013-2020 ($Million)
Table 111 RoW: Nuclear Medicine/Radiopharmaceutical Beta Emitters Market Size, By Type, 2013–2020 ($Million)
Table 112 RoW: Radiopharmaceutical Brachytherapy Market Size, By Type, 2013–2020 ($Million)
Table 113 RoW: Radiopharmaceutical Therapeutic Market Size, By Application, 2013-2020 ($Million)
 
 
List of Figures (55 Figures)
 
Figure 1 Market Segmentation
Figure 2 Research Methodology Steps
Figure 3 Break Down of Primary Interviews: By Company Type, Designation, and Region
Figure 4 Market Size Estimation Methodology: Bottom-Up Approach
Figure 5 Market Size Estimation Methodology: Top-Down Approach
Figure 6 Data Triangulation Methodology
Figure 7 Diagnostics Market to Witness Highest Growth Rate From 2015 to 2020
Figure 8 Global Radiopharmaceuticals Therapeutics Market Share, By Type, 2015–2020
Figure 9 Geographical Snapshot of the Global Nuclear Medicine Market
Figure 10 Nuclear Medicine/Radiopharmaceuticals SPECT Applications, 2015–2020
Figure 11 Advances in Radiotracers to Propel Market Growth
Figure 12 North America Dominates the SPECT Nuclear Medicine Diagnostics Market in 2015
Figure 13 Asia-Pacific to Witness Highest Growth Rate During the Forecast Period
Figure 14 Diagnostics Segment to Command the Largest Market Share in the Forecast Period
Figure 15 Nuclear Medicine Market: Drivers, Restraints, Challenges, & Opportunities
Figure 16 Global Nuclear Medicine Market, By Type
Figure 17 Nuclear Medicine Therapeutic Segment to Grow at the Highest CAGR of 10.5%
Figure 18 PET Segment to Grow at the Highest CAGR of 11.7% During the Forecast Period
Figure 19 Alpha Emitters Segment to Grow at the Highest CAGR of 17.3% During the Forecast Period
Figure 20 Asia-Pacific to Grow at the Highest CAGR of 9.4% in the Forecast Period
Figure 21 The Neurology Application Segment to Grow at the Highest CAGR of 8.4% During the Forecast Period
Figure 22 Asia-Pacific to Grow at the Highest CAGR of 13.1% in the Forecast Period
Figure 23 The Neurology Application Segment is Projected to Grow at the Highest CAGR of 12.9% During the Forecast Period
Figure 24 Asia-Pacific to Grow at the Highest CAGR of 12.2% in the Forecast Period
Figure 25 The Neurology Application Segment is Expected to Grow at the Highest CAGR of 11.3% During the Forecast Period
Figure 26 North America Commands Largest Share of the Global Nuclear Medicine Diagnostic Market in 2015
Figure 27 North America Witness A CAGR of 8.1% in the Global Nuclear Medicine Diagnostic Market
Figure 28 European Nuclear Medicine Diagnostic Market to Grow at A CAGR of 7.1%
Figure 29 Asia-Pacific to Witness A CAGR of 10.1% in the Global Nuclear Medicine/Radiopharmaceuticals Diagnostic Market
Figure 30 RoW Nuclear Medicine/Radiopharmaceuticals Diagnostic Market Will Grow at A CAGR of 9%
Figure 31 North America is Expected to Command the Largest Share of the Global Nuclear Medicine Therapeutic Market in 2015
Figure 32 North America to Witness A CAGR of 10% in the Global Nuclear Medicine Therapeutic Market During the Forecast Period
Figure 33 Europe to Witness A CAGR of 9.8% in the Global Nuclear Medicine Therapeutic Market
Figure 34 Asia-Pacific Nuclear Medicine Therapeutic Market to Grow at A CAGR of 12.2% in the Forecast Period
Figure 35 The Global Radiopharmaceutical Therapeutic Market in RoW is Expected to Grow at A CAGR of 8.7% During the Forecast Period
Figure 36 Market Share Analysis, By Key Player, 2014
Figure 37 Strategies Adopted By Key Players Over the Last Three Years (2012-2015)
Figure 38 Battle for Market Share: Agreements/Contracts/Partnerships Was the Key Strategy
Figure 39 Agreements, Contracts, and Partnerships, 2012-2015
Figure 40 Acquisitions, 2012-2015
Figure 41 Market Development, 2012-2015
Figure 42 Expansions, 2012-2015
Figure 43 New Product Launches, 2012-2015
Figure 44 Other Strategies, 2012-2015
Figure 45 Geographical Revenue Mix of Key Players in the Market
Figure 46 Cardinal Health, Inc.: Company Snapshot
Figure 47 Mallinckrodt PLC: Company Snapshot
Figure 48 GE Healthcare: Company Snapshot
Figure 49 Lantheus Medical Imaging: Company Snapshot
Figure 50 Bayer Healthcare: Company Snapshot
Figure 51 Bracco Imaging S.P.A: Company Snapshot
Figure 52 Eczacibasi-Monrol Nuclear Products: Company Snapshot
Figure 53 Nordion, Inc.: Company Snapshot
Figure 54 Advanced Accelerator Applications S.A.: Company Snapshot
Figure 55 IBA Molecular Imaging: Company Snapshot

Nuclear medicine/radiopharmaceuticals are drugs that contain radionuclide-emitting ionizing radiation, used in the nuclear imaging field to diagnose and treat diseases. The radiopharmaceuticals market is bifurcated into diagnostics and therapeutics segments. Radiopharmaceuticals in the diagnostics market are categorized as SPECT and PET; whereas, radiopharmaceuticals in the therapeutics market are categorized as beta emitters, brachytherapy isotopes, and alpha emitters.

The global radiopharmaceuticals market is segmented on the basis of type, application, and region. Based on type, the nuclear medicine market is categorized into diagnostics and therapeutics segments. In 2014, the diagnostics segment accounted for the largest share of the nuclear medicine market. The diagnostics segment is further segmented into SPECT and PET. In 2014, the SPECT segment accounted for the largest share of the radiopharmaceuticals diagnostics market. The therapeutics segment is further segmented into beta emitters, alpha emitters, and brachytherapy isotopes. In 2014, the beta emitters segment accounted for the largest share of the radiopharmaceuticals therapeutics market.

Based on applications, the nuclear medicine market is segmented into diagnostics (SPECT and PET) and therapeutics applications. In 2014, the diagnostics segment accounted for the largest share of the nuclear medicine market.

Factors such as advances in radiotracers, alpha radio immunotherapy-based targeted cancer treatment, and increasing number of patients with cancer and cardiovascular aliments are driving the growth of this market. Moreover, potential radioisotopes in the pipeline, high demand from emerging countries, and advances in neurological applications are likely to create huge opportunities for this market in the coming years. However, factors such as shorter half-life of radiopharmaceuticals, stringent regulatory guidelines, and competition from conventional diagnostic procedures are hindering the growth of this market.

On the basis of regions, the radiopharmaceuticals market is classified into North America, Europe, Asia-Pacific, and the Rest of the World (RoW).

Global Nuclear Medicine/Radiopharmaceuticals Market Size, by Region, 2015 - 2020

Nuclear Medicine/Radiopharmaceuticals Market

Note: The size of the bubble chart depicts the market size ($Million) in 2015.

Source: Organisation for Economic Co-operation and Development (OECD), European Association of Nuclear Medicine (EANM), National Institutes of Health (NIH), World Nuclear Association (WNA), International Atomic Energy Agency (IAEA), Nuclear Regulatory Commission (NRC), Society of Nuclear Medicine and Molecular Imaging (SNMMI), Nuclear Energy Agency (NEA), Board of Radiation and Isotope Technology (BRIT), Australian Nuclear Science and Technology Organisation (ANSTO), Canadian Nuclear Association (CNA), Nuclear Medicine Associations, Experts Interviews, and MarketsandMarkets Analysis

The global radiopharmaceuticals market is expected to reach $6.96 Billion by 2020 from $4.50 Billion in 2015, growing at a CAGR of 9.1% from 2015 to 2020. The market is dominated by North America, followed by Asia-Pacific, Europe, and the Rest of the World (RoW) regions. The Asia-Pacific region is expected to grow at the fastest rate during the forecast period.

Some of the major players in the global nuclear medicine market include Cardinal Health, Inc. (U.S.), GE Healthcare (U.K.), Bracco Imaging S.p.A (Italy), Eczacibasi-Monrol Nuclear Products (Turkey), Nordion, Inc. (Canada), Advanced Accelerator Applications S.A. (France), Bayer Healthcare (Germany), Lantheus Medical Imaging, Inc. (U.S.), IBA Molecular Imaging (Belgium), and Mallinckrodt plc (Ireland).

Custom Market Research Services

We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Please visit http://www.marketsandmarkets.com/knowledge-process-outsourcing-services.asp to specify your custom Research Requirement

Connect With Us

Follow us on LinkedIn  Follow us on Facebook   Follow us on Twitter 
Live Chat Support


US : 1-888-600-6441
UK : 44-800-368-9399

Search reports